Sign In
Buy BDSX
$16.10
+0.660 (+4.27%)
At Close: Jun 03, 2026
Biodesix, Inc. (BDSX) Q3 2022 Earnings Call Transcript
09:53am, Sunday, 06'th Nov 2022
Biodesix, Inc. (NASDAQ:BDSX ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Representatives Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer C
Biodesix, Inc. (BDSX) Reports Q3 Loss, Tops Revenue Estimates
08:17am, Thursday, 03'rd Nov 2022
Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of -6.25% and 1.90%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Biodesix to Report Third Quarter 2022 Financial Results on November 3, 2022
06:00am, Thursday, 20'th Oct 2022
BOULDER, Colo.
Biodesix to Participate in Two Upcoming Investor Conferences in September
06:00am, Tuesday, 06'th Sep 2022
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton,
Biodesix, Inc. (BDSX) CEO Scott Hutton on Q2 2022 Results - Earnings Call Transcript
01:28pm, Saturday, 06'th Aug 2022
Biodesix, Inc. (NASDAQ:BDSX ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cow
Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates
08:17am, Thursday, 04'th Aug 2022
Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of 14.89% and 28.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Biodesix to Present at the Canaccord Genuity 42nd Annual Growth Conference
06:00am, Wednesday, 03'rd Aug 2022
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton,
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Young Kwa
Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022
06:00am, Tuesday, 19'th Jul 2022
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, today announced that it will r
Biodesix to Present at the 42nd Annual William Blair Growth Stock Conference
06:00am, Wednesday, 01'st Jun 2022
BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer o
Biodesix: Bad Diagnosis
12:45pm, Thursday, 26'th May 2022
Biodesix has been a terrible business and stock since its offering. Even a short-lived pandemic-related momentum run could not inspire confidence or profits.
Biodesix to Present at the H.C. Wainwright Global Investment Conference
06:00am, Tuesday, 17'th May 2022
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton,
Biodesix, Inc. (BDSX) CEO Scott Hutton on Q1 2022 Results - Earnings Call Transcript
11:48am, Wednesday, 11'th May 2022
Biodesix, Inc. (NASDAQ:BDSX ) Q1 2022 Earnings Conference Call May 11, 2022 8:00 AM ET Company Participants Chris Brinzey - IR Scott Hutton - President, CEO & Director Robin Cowie - CFO, Secretary & T
Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates
08:17am, Wednesday, 11'th May 2022
Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of -31.58% and 2.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Biodesix to Report First Quarter 2022 Financial Results on May 11, 2022
06:00am, Wednesday, 27'th Apr 2022
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will r
